Alector (ALEC) vs Fate Therapeutics (FATE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Alector (ALEC) over the past year, gaining 41.1% versus a loss of 34.4%. Over five years, ALEC leads with a -91.3% price change compared with -96.5% for FATE. Fate Therapeutics is the larger company by market cap ($261.2 million vs $232.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | FATE |
|---|---|---|
| Share price | $2.08 | $2.18 |
| Market cap | $232.25M | $261.21M |
| 1-day change | +2.97% | +2.35% |
| YTD return | +29.49% | +117.35% |
| 1-year return | -34.42% | +41.06% |
| 5-year return | -91.33% | -96.52% |
| EPS (TTM) | $-1.09 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $3.23 |
| 52-week low | $1.09 | $0.95 |
| Distance from 52-week high | -38.82% | -32.51% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +58.65% | +163.30% |
| Average volume | 2.86M | 1.86M |
| Shares outstanding | 111.66M | 119.82M |
| Employees | 103 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed ALEC by 75.5 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
ALEC vs FATE FAQ
Which is bigger, Alector or Fate Therapeutics?
Fate Therapeutics (FATE) is larger, with a market capitalization of $261.21M compared with $232.25M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or FATE?
FATE returned +41.06% over the past 12 months, compared with -34.42% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Fate Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.